Smith & Nephew Stock (NYSE:SNN), Trade Ideas

Smith & Nephew

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 41% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.

Dollar Photo by VAKS-Stock Agency on Shutterstock

Large Cap

News

Health Care

General

Smith &amp; Nephew shakes up executive pay structure, aligning with US standards to curb turnover. Chairman Rupert Soames addresses global talent recruitment challenges and the shift&#39;s significance in the competitive med-tech market.

British MedTech Firm Smith &amp; Nephew Seeks To Adopt US-Inspired Pay Policy to Navigate Shareholder Skepticism

Price Target

Small Cap

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

GOOGL

INVH

KIDS

Alphabet To Rally Over 10%? Here Are 10 Other Analyst Forecasts For Wednesday

Earnings

Guidance

Movers

Smith &amp; Nephew PLC (NYSE: SNN) reported improved revenue, profit, and margin in the 

Smith &amp; Nephew Raises Revenue Growth Outlook After Strong 1H Performance, Sports Medicine and Wound Management Show Strength

Smith & Nephew PLC

SIENNA RESOURCES INC ORD by SIENNA RESOURCES INC

Sienna Resources Inc

SIENNA BIOPHARMACEUTICALS by Sienna Biopharmaceuticals, Inc.

Sienna Biopharmaceuticals Inc

Sibannac Inc

Seneca Financial Corp

PPX Mining Corp

KINGWELL GROUP LTD ORD by Kingwell Group Ltd.

Kingwell Group Ltd

SENSEN NETWORKS LTD by SenSen Networks Limited

SenSen Networks Ltd

SMITH & NEPHEW PLC ORD by Smith & Nephew PLC

Sunniva Inc

The study found that due to the independent and non-bonded internal layers of ALLEVYN LIFE Dressing, a layer-on-layer sliding phenomenon occurs and allows for dissipation of mechanical energy that could otherwise be transferred to the patient in a bonded dressing.1

Smith+Nephew Announces New Evidence Supporting Allevyn Life Foam Dressing's Role In Pressure Injury Prevention

Smith+Nephew ((LSE:SN, NYSE:<a href="https://www.benzinga.com/stock/SNN#NYSE">SNN</a>), the global medical technology&nbsp;company, today announces the review of medical technologies guidance from the UK National Institute for Health and Care Excellence (NICE) for its PICO Single Use Negative Pressure Wound Therapy System (sNPWT). &nbsp;
NICE have reviewed ‘Medical Technology Guideline 43 PICO negative pressure wound dressings for closed surgical incisions' which recognises that Smith+Nephew's PICO sNPWT provides better clinical outcomes than standard dressings in patients at high risk of surgical site infections (SSIs), at similar overall cost. As a result, NICE has reconfirmed its guidance, that PICO sNPWT should be considered as an option for closed surgical incisions in patients who are at high risk of surgical site infections,1&nbsp;remains the same. Key high risk factors include a high body mass index (BMI), diabetes, renal insufficiency and smoking among others.2
In the recent NICE review, a total of 28 papers published after the original guidance were identified. These included 12 Randomised Control Trials (RCT), 1 Uncontrolled Randomised Trial, 8 cohort studies, 3 before and after studies, and 4 economic studies. The 24 clinical studies included a total of 7,790 patients with PICO sNPWT being used in 3,754.
NICE concluded that PICO sNPWT is associated with fewer SSIs and seromas compared with standard wound dressings. Cost modelling suggests that compared with standard wound dressings, PICO sNPWT provides extra clinical benefits at similar overall cost to the NHS.1 For some types of surgery, such as colorectal, cardiothoracic and vascular surgery PICO sNPWT provides cost savings.1&nbsp;
 &nbsp;
The PICO sNPWT dressing includes a proprietary AIRLOCK◊ Technology layer that delivers negative pressure wound therapy across a surgical incision and the surrounding zone of injury.3,4 This unique feature is designed to help reduce the risk of wound complications by reducing post-operative fluid5,6 and tension&#x2A;7 around a closed surgical incision. The combination of these actions helps reduce the risk of two common surgical site complications - surgical wound dehiscence and SSIs.8
"It's fitting that this recognition from NICE occurs during International Cesarean Awareness Month, as PICO sNPWT has been shown to help reduce the risk of SSI's for high-risk C-section patients,&#x2A;&#x2A;9-11 said Simon Tarry, Senior Vice President and General Manager, Advanced Wound Management for International Markets at Smith+Nephew. "PICO sNPWT provides significant productivity opportunities for healthcare systems, and improved outcomes for patients. We hope this recognition will help Smith+Nephew support our customers to achieve a new standard of care to reduce the growing burden of wound care on patients and health care professionals."

Biotech

Smith+Nephew's PICO Single Use Negative Pressure Wound Therapy System Provides Better Clinical Outcomes Versus Standard Of Care According To Uk National Institute For Health And Care Excellence

Smith+Nephew ((LSE:SN, NYSE:<a href="https://www.benzinga.com/stock/SNN#NYSE">SNN</a>), the global medical technology company, today announces it has been named the Preferred Sports Medicine Technology Partner of UFC – the world's premier mixed martial arts organization and one of the foremost global brands in all of sports. Under the terms of the multi-year partnership, Smith+Nephew will activate its brand through UFC's immense global presence to promote the repair, regeneration and recovery of Sports Medicine injuries through advanced technologies.
"We're thrilled to have Smith+Nephew join us for the first time as an Official UFC Partner," said Robby Miller, Vice President, UFC Global Partnerships. "Through hard work, significant investment, and groundbreaking innovations like the UFC Performance Institute, UFC has become the industry leader in athlete health and safety in combat sports. We're looking forward to advancing that mission by also promoting better health and recovery through technology solutions, such as those offered by Smith+Nephew, that will benefit UFC athletes and fans alike." &nbsp;
Smith+Nephew offers world-class Sports Medicine solutions including advanced technologies, instruments and implants that enable surgeons to perform minimally invasive surgery including the repair of soft tissue injuries and degenerative conditions of the shoulder, knee, hip and small joints. Recent advancements in its biological healing portfolio include the REGENETEN◊&nbsp;Bioinductive Implant and the newly acquired CARTIHEAL◊&nbsp;AGILI-C◊&nbsp;Cartilage Repair Implant. Backed by impressive clinical evidence, both technologies are transforming the way healthcare professionals treat soft tissue repair and helping improve patient outcomes versus the current standard of care.1,2
"Smith+Nephew's purpose is Life Unlimited – helping restore people's bodies and their self-belief by using technology to take the limits off living. We are proud to partner with UFC and share a common goal to get patients back in the game quickly, safely, and effectively," said Scott Schaffner, President Sports Medicine, Smith+Nephew. "The global reach and influence of UFC is unmatched by any other sports organization, and we look forward to this partnership spotlighting Smith+Nephew's leading-edge portfolio of Sports Medicine technology solutions with the UFC's global audience."
Beyond the Octagon, UFC and Smith+Nephew will collaborate on original content that will be distributed through UFC's popular digital and social channels, which reach more than 259 million users worldwide. Smith+Nephew will also have a branded presence throughout the UFC Performance Institutes in Las Vegas, Shanghai and Mexico City - the world's first mixed martial arts performance training, research, rehabilitation, and nutrition centers. The agreement also provides for an annual Brand Ambassador fund that will bring the partnership to life through appearances, content, and creative campaigns with UFC athletes.

Smith+Nephew Teams Up With UFC To Be First-Ever Preferred Sports Medicine Technology Partner

British multinational medical equipment manufacturing company&nbsp;Smith &amp; Nephew&nbsp;Plc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNN#NYSE">SNN</a>) is set to revamp its executive pay structure, signaling a departure from the U.K. market norms, as the company aims to align compensation with its U.S. counterparts.&nbsp;
In a move aimed at addressing high executive turnover, the FTSE 100 medical devices firm intends to bring its pay for U.S. executives closer to American levels, challenging the sustainability of U.K. pay packages, according to Chairman&nbsp;Rupert Soames.&nbsp;
Citing Soames, the Financial Times&nbsp;<a target="_blank" href="https://www.ft.com/content/231b93b6-d0f3-429f-ae33-a592203f4d27" rel="noreferrer noopener">highlighted</a>&nbsp;a group of companies, &#8220;Brilos,&#8221; which are British in listing only, emphasizing the disparity in revenue sources and the need for a global talent recruitment strategy.
This shift in pay policy is crucial for Smith &amp; Nephew, a company that has witnessed four CEOs in the past five years, with a history of executive clashes related to compensation.&nbsp;
The move also reflects a broader trend among U.K. listed companies with substantial overseas revenues, aiming to overcome shareholder reluctance in the upcoming AGM season.
Chairman Soames asserted that the current stance on pay is untenable, leading to the proposal of a pragmatic reform that diverges from the U.K. market.&nbsp;
The policy aims to put U.S.-based executives, like CEO&nbsp;Deepak Nath, on a trajectory towards higher pay in line with local competitors, recognizing the global variations in remuneration practices.
The reform comes amidst a broader debate on the competitiveness of the London stock market, as several companies with significant North American operations opt for a primary listing in the U.S.&nbsp;
Smith &amp; Nephew, however, affirms its commitment to maintaining its primary listing in London, emphasizing the need for a compelling reason to consider a shift.
Soames is optimistic about investor reception, noting a more open mindset than two years ago. The move by Smith &amp; Nephew reflects a strategic response to the dynamics of the med-tech market, where the majority of revenues and operational leadership reside in the U.S.
Price Action:&nbsp;SNN shares are up 0.37% at $28.04 on the last check Tuesday.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo by VAKS-Stock Agency on Shutterstock

British MedTech Firm Smith & Nephew Seeks To Adopt US-Inspired Pay Policy to Navigate Shareholder Skepticism

Smith+Nephew ((LSE:SN, NYSE:<a href="https://www.benzinga.com/stock/SNN#NYSE">SNN</a>), the global medical technology company, today announced they have entered into a Master Cooperative Research and Development Agreement (CRADA) with the U.S. Army Institute of Surgical Research (USAISR). This marks the first time that the USAISR has entered into a master agreement of this nature with an industry-leading medical technology company.
The Master CRADA represents an enterprise-wide opportunity for Smith+Nephew across all business units - Advanced Wound Management, Orthopaedics and Sports Medicine - to enter into multiple collaborative research efforts.
"Smith+Nephew has a rich history supporting the military and partnering with the USAISR on this agreement furthers our purpose of helping people live their Life Unlimited," said Rohit Kashyap, President, Advanced Wound Management and Commercial Operations at Smith+Nephew. "This agreement is exciting on many levels - not just for Smith+Nephew, but for our customers and their patients as well."
The agreement enables efficient collaboration and strengthens the relationship between the USAISR and Smith+Nephew for future research endeavours in diverse areas of mutual interest. These types of cooperative efforts benefit both the Department of Defense (DOD) and industry leaders by providing opportunities to conduct joint research and learn from each other.
"The pre-negotiated key terms and conditions of the Master CRADA provide the broad legal framework under which for multiple, future collaborative research efforts will be assigned. In addition to streamlining the research agreement process, this Master CRADA provides the foundation for a strategic, joint effort to leverage the infrastructure, expertise, and capabilities of both parties to support innovation that aims to address technical challenges to improving combat casualty care," said COL (Dr.) J. Brian Lanier, Commander, U.S. Army Institute of Surgical Research (USAISR).

Contracts

Smith+Nephew And U.S. Army Institute Of Surgical Research To Engage In Master Cooperative Research And Development Agreement

Smith &amp; Nephew (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNN#NYSE">SNN</a>) reported quarterly earnings of $0.83 per share. This is a 1.22 percent increase over earnings of $0.82 per share from the same period last year. The company reported $5.55 billion in sales this quarter. This is a 6.40 percent increase over sales of $5.21 billion the same period last year.

Smith & Nephew FY Adj EPS $0.83 Up From $0.82 YoY, Sales $5.55B Up From $5.21B YoY

Smith & Nephew SNATS Reports Q4 Revenue of $1.458B, up 6.8% YoY,

Smith+Nephew ((LSE:SN, NYSE:<a href="https://www.benzinga.com/stock/SNN#NYSE">SNN</a>), the global medical technology company, today announces full commercial availability of its AETOS Shoulder System in the US, along with 510(k) clearance for its use with ATLASPLAN◊ 3D Planning Software and Patient Specific Instrumentation for total shoulder arthroplasty. Total shoulder arthroplasty is one of the fastest growing segments in Orthopaedics with an estimated 250,000 procedures in the US by 2025.1 &nbsp;
Developed to restore patients' range-of-motion2-5 and help minimize arthritic shoulder pain, the AETOS Shoulder System features the Meta Stem which is designed for stability with metaphyseal fixation and an inlay collar, bone preservation, and to maintain patient anatomy.2,6,7
"After using the system for the past several months, I can say that the AETOS Shoulder System is a game changer," said Dr. Charles Jobin, Orthopaedic Surgeon at Columbia University Irving Medical Center. "With the stability of its Meta Stem, the flexibility the system provides and streamlined instrumentation, it is a great solution not only benefitting patients but surgeons alike."
Indicated for both anatomic and reverse total shoulder arthroplasty, the AETOS Shoulder System offers a compact yet comprehensive portfolio of solutions that enhance the surgical experience by enabling intraoperative flexibility. With fewer steps for conversion&#x2A;8 and fewer instruments for primary anatomic and reverse,&#x2A;8&nbsp;the system is designed to simplify the operating room flow.8 This also allows for an efficient solution, particularly of value in an Ambulatory Service Center (ASC) environment where sterilization and space limitations may be of concern.
"I'm thrilled with the stem fixation of the implant that the AETOS Shoulder System provides and believe it will be a noticeable, positive improvement for my patients," said Dr. Matthew Ramsey, Shoulder and Elbow Specialist at Rothman Orthopaedics. "I'm also very pleased with the instrumentation - especially the glenoid reamer being so low profile and easy to use."
&nbsp;
Smith+Nephew's AETOS Shoulder System
ATLASPLAN 3D Planning Software and Patient Specific Instrumentation enables pre-operative case planning for total shoulder arthroplasty, and was developed in partnership with Materialise NV, who has over 30 years of experience revolutionizing personalized solutions. It features:&nbsp;
<ul>
<li>A user-friendly online web-based planner for access from any computer or tablet.</li>
<li>Fast turnaround time from image upload to planning.</li>
<li>An optional 3D-printed glenoid guide, designed with the patented coracoid clip for stability, provides a reliable and accurate method to execute the surgical plan through conventional surgical techniques.9</li>
</ul>
The AETOS Shoulder System received 510(k) clearance from the United States Food and Drug Administration in June of 2023. It is the latest addition to Smith+Nephew's expanding Upper Extremity portfolio and complements our market-leading Sports Medicine shoulder repair solutions to enable biological healing.
To learn more please visit <a href="https://www.globenewswire.com/Tracker?data=Y2h5TGvNg-FV41enRputJdgrIgeTxce2EGhcTe2diaFMbl1-7Yl1xcWf-XVA5ysV7tCresN6QIm8ZvgCPieKRL54nYKt_uhuKOOxsqDvRuZ30bBaUwAIV_Ngx4UJm-7B">www.smith-nephew.com/aetos</a> or visit the Smith+Nephew booth (#5469) at the American Academy of Orthopaedic Surgeons 2024 Annual Meeting from February 12-16 in San Francisco, CA.
- ends -
Enquiries
<figure class="table"> 
<table>
<tbody>
<tr>
<td>Media David Snyder&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; +1 978-749-1440 Smith+Nephew &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td>
</tr>
</tbody>
</table>
</figure>
References
<ol>
<li>SmartTrak Report, 2023</li>
<li>Smith+Nephew 2023. AETOS Inlay Design Features. Internal Report. ER-04-0990-0017.</li>
<li>Arenas-Miquelez A, Murphy R, Rosa A, Caironi D, Zumstein M. Impact of humeral and glenoid component variations on range of motion in reverse geometry total shoulder arthroplasty. A standardised computer model study. (8214). Swiss Medical Weekly. 2020;150(SUPPL 244):2S.</li>
<li>Kalouche I, Sevivas N, Wahegaonker A, Sauzieres P, Katz D, Valenti P. Reverse shoulder arthroplasty: Does reduced medialisation improve radiological and clinical results? Acta Orthopaedica Belgica. 2009;75(2):158-166.</li>
<li>Lädermann A, Tay E, Collin P, et al. Effect of critical shoulder angle, glenoid lateralization, and humeral inclination on range of movement in reverse shoulder arthroplasty. Bone Joint Res. 2019;8(8):378-386.</li>
<li>Smith+Nephew 2023. AETOS Anatomic Humeral Head Design. Internal Report. ER-04-0990-0019.</li>
<li>Harmer L, Throckmorton T, Sperling JW. Total shoulder arthroplasty: are the humeral components getting shorter? Curr Rev Musculoskelet Med. 2016;9(1):17-22.</li>
<li>Smith+Nephew 2023. AETOS Instruments &amp; Trays. Internal Report. ER-04-0990-0020.</li>
<li>Materialise 3D Shoulder Planner &amp; Guides. Materialise nv L-103300-01</li>
</ol>
&#x2A;Compared to a competitive shoulder system

Smith+Nephew Announces Commercial Launch Of Its AETOS Shoulder System For Anatomic And Reverse Shoulder Replacement At AAOS 2024 Annual Meeting

Smith+Nephew Announces Results For Its REGENETEN Bioinductive Implant From A Recently Completed Randomized Controlled Trial, Showing The Implant Reduces Full-thickness Rotator Cuff Re-tear Rates By 68%

Smith+Nephew To Acquire CartiHeal, Developer Of Agili-C, A Sports Medicine Technology For Cartilage Knee Regeneration, For An Initial Cash Consideration Of $180M And Up To A Further $150M As Contingent Payment

Smith+Nephew Opens New Surgical Innovation And Training Centre In The Heart Of Munich

<ul>
<li>Citigroup raised the price target for LyondellBasell Industries N.V. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lyb#NYSE">LYB</a>) from $104 to $106. Citigroup analyst Patrick Cunningham upgraded the stock from Neutral to Buy. LyondellBasell Industries shares gained 0.4% to close at $93.79 on Tuesday.</li>
<li>Piper Sandler lowered B&amp;G Foods, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bgs#NYSE">BGS</a>) price target from $14 to $8. Piper Sandler analyst Michael Lavery downgraded the stock from Neutral to Underweight. B&amp;G Foods shares fell 4.5% to $9.05 in pre-market trading.</li>
<li>Keybanc cut the price target for Invitation Homes Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/invh#NYSE">INVH</a>) from $37 to $35. Keybanc analyst Austin Wurschmidt maintained an Overweight rating. Invitation Homes shares fell 0.7% to close at $31.07 on Tuesday.</li>
<li>Telsey Advisory Group slashed the price target for Lowe&#39;s Companies, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/low#NYSE">LOW</a>) from $230 to $225. Telsey Advisory Group analyst Joseph Feldman maintained a Market Perform rating. Lowe&#39;s shares rose 0.1% to $200.32 in pre-market trading.</li>
<li>UBS raised Fluor Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/flr#NYSE">FLR</a>) price target from $35 to $47. UBS analyst Steven Fisher upgraded the stock from Neutral to Buy. Fluor shares fell 2.7% to close at $34.62 on Tuesday.</li>
<li>Jefferies cut Trinseo PLC (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tse#NYSE">TSE</a>) price target from $22 to $9. Jefferies analyst Laurence Alexander downgraded the stock from Buy to Hold. Trinseo shares fell 1.1% to $8.20 in pre-market trading.</li>
<li>BTIG lowered OrthoPediatrics Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kids#NASDAQ">KIDS</a>) price target from $59 to $52. BTIG analyst Ryan Zimmerman maintained a Buy rating. OrthoPediatrics shares fell 0.8% to close at $31.51 on Tuesday.</li>
<li>Barclays cut PepsiCo, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pep#NASDAQ">PEP</a>) price target from $198 to $179. Barclays analyst Lauren Lieberman maintained an Overweight rating. PepsiCo shares rose 0.1% to $167.91 in pre-market trading.</li>
<li>B of A Securities raised the price target for Alphabet Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/googl#NASDAQ">GOOGL</a>) from $142 to $146. B of A Securities analyst Justin Post maintained a Buy rating. Alphabet shares fell 1.3% to close at $132.43 on Tuesday.</li>
<li>JP Morgan cut Meta Platforms, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/meta#NASDAQ">META</a>) price target from $425 to $400. JP Morgan analyst Doug Anmuth maintained an Overweight rating. Meta shares fell 0.4% to $299.71 in pre-market trading.</li>
<li>Bernstein slashed Smith &amp; Nephew plc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/snn#NYSE">SNN</a>) price target from $37 to $33. Bernstein analyst Lisa Bedell Clive maintained an Outperform rating. Smith &amp; Nephew shares rose 0.4% to $23.85 in pre-market trading.</li>
</ul>
Check This Out: <a href="https://www.benzinga.com/news/earnings/23/10/35081467/rpm-international-acuity-brands-and-3-stocks-to-watch-heading-into-wednesday"> RPM International, Acuity Brands And 3 Stocks To Watch Heading Into Wednesday </a>

Bernstein analyst Lisa Bedell Clive maintains Smith &amp; Nephew (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNN#NYSE">SNN</a>) with a Outperform and lowers the price target from $37 to $33.

Bernstein Maintains Outperform on Smith & Nephew, Lowers Price Target to $33

Smith &amp; Nephew PLC&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/snn#NYSE">SNN</a>) reported improved revenue, profit, and margin in the&nbsp;<a class="editor-rtfLink" href="https://www.smith-nephew.com/en/news/2023/08/03/20230803-sn-second-quarter-and-first-half-2023-results" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">first half</a>, progressing towards achieving sustainable higher growth under its 12-point plan.
The medical equipment manufacturing company&#39;s 1H revenue rose 5.2% Y/Y (underlying growth of 7.3%) to $2.73 billion, while operating profit climbed to $275 million from $242 million.
Trading profit decreased to $417 million from $440 million. Adjusted EPS slipped to 34.9 cents from 38.1 cents.
For Q2, the company&#39;s revenues increased 6.6% (7.8% underlying) to $1.38 billion.
<ul>
<li>Orthopaedics revenue is up 5.8% (4.6% reported), reflecting higher procedure volumes, accelerating robotics adoption, and reducing the China VBP headwind.</li>
<li>Sports Medicine &amp; ENT is up 12.0% (10.4% reported), with strong growth across shoulder and knee repair.</li>
<li>Advanced Wound Management is up 6.2% (5.5% reported), led by double-digit growth from our negative pressure wound therapy portfolio.</li>
</ul>
Smith &amp; Nephew, which makes orthopedic implants and prosthetics, wound dressings, and other surgical technologies, also announced that its CFO Anne-Fran&ccedil;oise Nesmes will step down during the second quarter of 2024, the board has initiated an external search for a successor.
Guidance: Smith &amp; Nephew increased full-year underlying revenue growth guidance to 6.0%-7.0% (previously 5.0% to 6.0%).&nbsp;
It left trading profit margin guidance unchanged of at least 17.5%.
Price Action:&nbsp;SNN shares are down 2.84% at $28.47 on the last check Thursday.

Smith & Nephew Raises Revenue Growth Outlook After Strong 1H Performance, Sports Medicine and Wound Management Show Strength

MYGN

MYPS

NGVC

NINE

NNBR

NSIT

NSTG

NTLA

NTRA

NVMI

OCSL

OLED

ONEW

OPEN

ORLA

ORTX

OSUR

OTEX

PACK

PBPB

PBYI

PCTY

PGNY

PGTI

PHAR

PLNT

PLYA

PLYM

POST

POWI

PRDO

PRTA

PRVA

PTCT

PTLO

PowerShares Exchange Traded Fund Trust Dynamic Mid Cap Value Portfolio

PZZA

QLYS

RARE

RDFN

REFR

REGN

REZI

RYAN

SABR

SAND

SBLK

SEMR

SGHT

SHAK

SNCY

SNDX

SRTS

STEM

STEP

STKS

STWD

Earnings Scheduled For August 3, 2023

Management

Smith & Nephew's CFO Anne-Françoise Nesmes To Step Down In Q2 2024; The Board Has Initiated An External Search For Successor

Smith & Nephew Increased 2023 Underlying Revenue Growth Guidance To 6.0%-7.0%, Previously 5.0%-6.0%, Keeps Trading Profit Margin Guidance Unchanged Of At Least 17.5%.

Smith &amp; Nephew (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNN#NYSE">SNN</a>) reported quarterly earnings of $0.35 per share. This is a 8.4 percent decrease over earnings of $0.38 per share from the same period last year. The company reported $2.73 billion in sales this quarter. This is a 5.15 percent increase over sales of $2.60 billion the same period last year.

Smith & Nephew H1 EPS $0.35 Down From $0.38 YoY, Sales $2.73B Up From $2.60B YoY

U.S. stocks traded mixed, with the Dow Jones dropping around 30 points on Monday. Here are some big stocks recording losses in today&rsquo;s session.
<ul>
<li>Protagonist Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ptgx#NASDAQ">PTGX</a>) shares dipped 36.4% to $17.60.</li>
<li>TOP Financial Group Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/top#NASDAQ">TOP</a>) shares dropped 12.4% to $8.23. TOP Financial shares gained over 20% on Friday after the company reported FY23 financial results.</li>
<li>Icosavax, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/icvx#NASDAQ">ICVX</a>) fell 9.8% to $8.96.</li>
<li>Astrotech Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/astc#NASDAQ">ASTC</a>) dropped 9.4% to $12.85.</li>
<li>Rackspace Technology, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rxt#NASDAQ">RXT</a>) fell 8.5% to $2.49.</li>
<li>Avadel Pharmaceuticals plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/avdl#NASDAQ">AVDL</a>) dropped 7.8% to $15.18.</li>
<li>AstraZeneca PLC (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/azn#NASDAQ">AZN</a>) fell 7.4% to $66.30 as the company reported high-level results from the TROPION-Lung01 Phase 3 trial of datopotamab deruxtecan (Dato-DXd) in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) treated with at least one prior therapy.</li>
<li>GDEV Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gdev#NASDAQ">GDEV</a>) dropped 7% to $5.87.</li>
<li>ECARX Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ecx#NASDAQ">ECX</a>) fell 6.6% to $6.50. ECARX Holdings announced its intention to increase its investment and take a controlling stake in JICA Intelligent Robotics Co., Ltd.</li>
<li>MediaAlpha, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/max#NYSE">MAX</a>) dropped 6.1% to $9.69. MediaAlpha 10% owner WM Hinson Bermuda Ltd acquired a total of 5,916,816 shares an average price of $10.00.</li>
<li>Smith &amp; Nephew plc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/snn#NYSE">SNN</a>) fell 5.6% to $30.44.</li>
<li>BlackBerry Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bb#NYSE">BB</a>) dropped 4.3% to $5.30. BlackBerry recently reported better-than-expected first-quarter results.</li>
</ul>

&nbsp;
Read More: <a href="https://www.benzinga.com/markets/cryptocurrency/23/07/33096671/ethereum-tops-this-key-level-celo-the-graph-among-top-gainers"> Ethereum Tops This Key Level; Celo, The Graph Among Top Gainers</a>

Penny Stocks

Intraday Update

ASTC

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

GDEV

ICVX

PTGX

AstraZeneca, ECARX Holdings And Other Big Stocks Moving Lower On Monday

Industry giant Morgan Stanley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MS#NYSE">MS</a>) is shaking up its model for income-focused investors, indicating a strategic move towards robust and resilient players. The multinational investment bank told investors Thursday that it added new positions and adjusted weights in its <a href="https://www.benzinga.com/yield-investments">dividend portfolio</a>.
What Happened: Morgan Stanley introduced two new names: mining conglomerate Rio Tinto plc ADR Common Stock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RIO#NYSE">RIO</a>) and medical technology business Smith &amp; Nephew plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNN#NYSE">SNN</a>), while it rung the register on Amgen, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) and the iShares MSCI Hong Kong ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EWH#NYSE">EWH</a>).
Strategist Kevin Demers explained Rio Tinto&#8217;s addition was driven by three factors: China&#8217;s likely announcement of a stimulus that could bolster commodity demand, Rio Tinto&#8217;s best-in-class balance sheet and underappreciated earnings power, and the company&#8217;s attractive valuation with a current spot free-cash-flow yield of 9%, <a href="https://seekingalpha.com/news/3983853-morgan-stanley-shakes-up-its-global-dividend-portfolio">according to</a> Seeking Alpha, which originally covered the portfolio changes. Read Also: <a href="https://www.benzinga.com/markets/asia/23/06/33050727/the-us-is-trying-to-weaken-chinas-semiconductor-industry-heres-what-china-is-doing-to-fight-back-in">The US Is Trying To Weaken China&#8217;s Semiconductor Industry: Here&#8217;s What China Is Doing To Fight Back In AI Race</a>
Smith &amp; Nephew's inclusion is also a result of three main factors: its potential for self-help, recovery of elective procedure volume in the medical sector, and its attractive valuation.
Morgan Stanley&#8217;s decision to drop EWH is strategic, opting for Rio Tinto, a company with significant exposure to China. The change could bring potential benefits from any easing by the Chinese government aimed to stimulate the economy, and consequently, a rebound in global economic growth.
Morgan Stanley removed Amgen, citing it could no longer provide a rating on the stock.
The investment bank is increasing weights in TotalEnergies SE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TTE#NYSE">TTE</a>) and the WisdomTree Emerging Markets High Dividend Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DEM#NYSE">DEM</a>), while reducing its weight in Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>).
The portfolio&#8217;s new composition suggests a focus on companies with strong balance sheets, resilience during challenging economic periods, and exposure to regions with potential for economic rebound and growth.
Read Next: <a href="https://www.benzinga.com/trading-ideas/long-ideas/23/06/33046519/how-to-earn-500-a-month-from-zim-integrated-shipping-stock">How To Earn $500 A Month From ZIM Integrated Shipping Stock</a>
Photo: Shutterstock

Analyst Color

Long Ideas

Mid Cap

Sector ETFs

Dividends

Specialty ETFs

Emerging Market ETFs

Global

ETFs

AMGN

Amgen Out, Rio Tinto In As Morgan Stanley Shuffles Dividend Deck

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
There are some robotic surgery stocks for investors to buy in March this year. The growth of robotic-assisted surgery has been driven by its potential benefits, such as smaller incisions, reduced pain and scarring, quicker recovery times, and improved clinical outcomes.



I think that investing in robotic surgery stocks is an underrated thematic choice for investors. The reason being is that there is <a href="https://cworldwide.com/insights-news/item/?id=5922&amp;title=advancement-in-robotic-surgery">currently a very low industry penetration</a> of using robots in the surgical market, which means there is potentially money on the table for early investors to take advantage of.



Robotic surgical systems market is <a href="https://www.medicaldevice-network.com/analyst-comment/robotic-surgical-systems-market-displaying-continued-growth/">projected to grow</a> from $3.3 billion in 2023 to $7.2 billion in 2033, with a CAGR of 15.7%. However, barriers include high costs and limited surgeon training, particularly in developing markets.



Still, I firmly believe that robotic surgery stocks is pioneering where the surgical industry is ultimately heading, especially as the average cost of these systems falls and their floorspaces become more efficient.



So here are seven robot surgery stocks for investors to buy in March this year.



<h2>Intuitive Surgical (ISRG)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/02/isrg-stock-300x169.jpg" alt="A sign with the Intuitive Surgical logo standing outside of a company office. ISRG stock."><div>Source: Sundry Photography / Shutterstock.com</div></div>Intuitive Surgical (NASDAQ:<a href="https://investorplace.com/stock-quotes/isrg-stock-quote/">ISRG</a>) is known for its da Vinci surgical systems, used globally for a variety of procedures.



In Q4 2023, ISRG <a href="https://seekingalpha.com/article/4664538-intuitive-surgical-inc-isrg-q4-2023-earnings-call-transcript">showed strong performance</a> with a 21% increase in da Vinci procedures and a 14% growth in the installed base of systems to 8,606. The full year saw a 9% increase in average system utilization. Revenue for Q4 was $1.93 billion, marking a 17% increase from the previous year, and lLeasing accounted for 48% of Q4 placements.



For 2024, ISRG anticipates a <a href="https://seekingalpha.com/news/4053715-biggest-stock-movers-today-alcon-intuitive-surgical-and-more">13% to 16% increase in procedures</a> compared to 2023, fueled by a 25% rise in U.S. general surgery procedures.



The market seems to be bullish on ISRG&rsquo;s general trajectory as it has a forward P/E ratio of 61 times earnings and analysts rate <a href="https://stockanalysis.com/stocks/isrg/forecast/">the company as a &ldquo;Buy&rdquo;</a>.



Although it may trade at a premium compared with its peer companies, ISRG is the leading brand in robotic surgeries worldwide, and I feel that is expected to continue.



<h2>Stryker (SYK)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/04/syk1600-300x169.jpg" alt="The Stryker (SYK) office in Fremont, California."><div>Source: Sundry Photography / Shutterstock.com</div></div>Stryker (NYSE:<a href="https://investorplace.com/stock-quotes/syk-stock-quote/">SYK</a>) offers the Mako robotic arm, enhancing joint replacement surgery with precision.



The Mako system utilizes a robotic arm to assist surgeons during knee and hip replacement procedures. It provides high precision capabilities by relying on a patient&rsquo;s specific CT scan data to create a 3D model and plan the surgery.



This system seems to be popular, as&nbsp; for FY23, <a href="https://seekingalpha.com/article/4660546-stryker-stock-mako-shoulder-and-spine-launches-are-on-the-way">Stryker forecasted</a> a robust 10.5% organic revenue growth, with further expectations of maintaining a 10% growth rate into FY24.



For Q4 2023, Stryker <a href="https://www.benzinga.com/news/earnings/24/01/36856700/stryker-stock-gains-on-q4-earnings-2024-outlook">reported better-than-expected financial results</a>, with an adjusted earnings per share (<a href="https://investorplace.com/stock-quotes/eps-stock-quote/">EPS</a>) of $3.46, surpassing the anticipated $3.27, and a revenue of $5.82 billion, exceeding estimates of $5.60 billion.



The company estimates organic net sales growth between 7.5% and 9.0% for 2024, with an adjusted EPS range of $11.70 to $12, and it&rsquo;s perhaps one of the best alternative to ISRG for investors interested in these robotics stocks to buy.



<h2>Becton, Dickinson and Company (BDX)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/08/bdx-stock-1-300x169.jpg" alt="The front of a Becton Dickinson (BDX) office in Ontario, Canada."><div>Source: JHVEPhoto / Shutterstock.com</div></div>Becton, Dickinson and Company (NYSE:<a href="https://investorplace.com/stock-quotes/bdx-stock-quote/">BDX</a>) specializes in medical devices and instrument systems.



One of BDX&rsquo;s key robotic surgery products is the Auriga Robotic Endovascular System. The Auriga system integrates robotics, advanced imaging, and instrumentation to provide precise vascular intervention.



I think that now is a good time for investors to pick up shares of BDX stock. The reason being is that the company <a href="https://seekingalpha.com/news/4061128-becton-dickinson-reports-mixed-q1-results-raises-fy24-outlook">raised its full-year adjusted EPS guidance</a> and the midpoint of organic revenue growth, now expecting fiscal year 2024 revenues to range between approximately $20.2 billion to $20.4 billion.&nbsp;



This is an increase from the previous forecast of $20.1 billion to $20.3 billion. This update includes an expectation for fiscal year 2024 adjusted diluted EPS to be $12.82 to $13.06, adjusted from $12.70 to $13.00 previously&#8203;.



Investing in BDX can be accretive, thanks to the robotics market gradually shifting from a consolidated one to one that&rsquo;s more fractured and decentralized.



<h2>Zimmer Biomet Holdings (ZBH)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/10/biomedical-technology1600-300x169.png" alt="Modern Medical Research Laboratory with Computer, Microscope, Glassware with Biochemicals on the Desk. Scientific Lab Biotechnology Development Center Full of High-Tech Equipment. Biomedical technology stocks, RSLS Stock"><div>Source: Gorodenkoff / Shutterstock.com</div></div>Zimmer Biomet Holdings (NYSE:<a href="https://investorplace.com/stock-quotes/zbh-stock-quote/">ZBH</a>) is a leader in medical technology with its ROSA robotics platform. This platform is designed specifically for total knee replacement procedures.



ZBH is another one of those robotics stocks that investors should consider buying, and there could be an attractive entry point to scoop up shares.



The company has initiated a <a href="https://www.marketscreener.com/quote/stock/ZIMMER-BIOMET-HOLDINGS-IN-14996/news/Zimmer-Biomet-forecasts-upbeat-2024-profit-on-steady-medical-devices-demand-45913607/">restructuring program</a> aimed at cutting costs, expecting run-rate savings of about $200 million by 2025. ZBH also anticipates full-year 2024 profit in the range of $8-$8.15 per share, surpassing analysts&rsquo; expectations of $7.95. Moreover, ZBH projects its full-year revenue to grow between 5% to 6% on a constant currency basis.



I think that ZBH is one of the cheaper robotics stocks for investors to buy. Its forward P/E is just 15 times earnings, and analysts gave it a &ldquo;Hold&rdquo; rating. However, I think that some caution is being given amid ZBH&rsquo;s restructuring, and this is giving it a discount to its intrinsic value, which could be higher than its share price reflects.



<h2>Smith &amp; Nephew (SNN)</h2>



<div><img width="300" height="165" src="https://investorplace.com/wp-content/uploads/2017/04/snnmsn-300x165.jpg" alt="Smith &amp; Nephew plc (ADR) (SNN)"><div>Source: Shutterstock</div></div>Smith &amp; Nephew (NYSE:<a href="https://investorplace.com/stock-quotes/snn-stock-quote/">SNN</a>) focuses on orthopedic reconstruction and sports medicine.



In the orthopedic robotics arena, Smith &amp; Nephew has partnered with Brainlab to co-market the ROBOTICS KNEE platform for total knee replacement procedures. Key features include robotic control during the bone cutting process, integrated navigation software, and patient-specific 3D planning based on medical imaging.



Looking ahead, SNN expects an <a href="https://www.marketscreener.com/quote/stock/SMITH-NEPHEW-PLC-9590181/news/Smith-Nephew-plc-Provides-Earnings-Guidance-for-2024-46058224/">underlying revenue growth</a> in the range of 5% to 6% (4.6% to 5.6% reported) and targeting a trading profit margin of at least 18%.



As a smaller company with a market cap of just 12 billion, SNN <a href="https://stockanalysis.com/stocks/snn/forecast/">could be accretive</a> for investors who buy shares while the company is still in its infancy. The newness of the business has also led some analysts to set bullish projections for the firm.&nbsp;



One analyst expects SNN&rsquo;s EPS to increase 71.22% this year, rising to 1.03. There is also a slight upside for its stock price at the time of writing.



<h2>Globus Medical (GMED)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/07/medical-bills-1600-300x169.png" alt="Doctor or physician calculating a patients medical bills at a desk. Medical bills, health costs, health expenses."><div>Source: THICHA SATAPITANON / Shutterstock</div></div>Globus Medical (NYSE:<a href="https://investorplace.com/stock-quotes/gmed-stock-quote/">GMED</a>) is known for its innovation in musculoskeletal solutions. Meanwhile, in the robotic surgery market, GMED has the ExcelsiusGPS robotic navigation platform for spine procedures. Key applications include robotic trajectory guidance for pedicle screw placement during spine surgeries like fusions, decompressions, etc.



GMED <a href="https://finance.yahoo.com/news/globus-medical-inc-gmed-posts-215407157.html">reported significant financial achievements in 2023</a>, including record worldwide net sales of $616.5 million in Q4 and $1.568 billion for the full year. This growth was largely driven by its merger with NuVasive and increased product volumes. Meanwhile, non-GAAP net income rose by 38.9%, and the company reaffirmed its full-year 2024 revenue guidance range of $2.450 billion to $2.475 billion, with non-GAAP EPS between $2.68 to $2.7.



The company also expects to achieve $170 million in synergies from the NuVasive merger over the next three years, and is one of the key reasons that I feel investors should consider buying GMED stock over the long-run.



<h2>Medtronic (MDT)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/08/mdt-stock-1-300x169.jpg" alt="Medtronic (MDT) sign outside office building representing healthcare stocks"><div>Source: JHVEPhoto / Shutterstock.com</div></div>Medtronic (NYSE:<a href="https://investorplace.com/stock-quotes/mdt-stock-quote/">MDT</a>) is a leader in medical technology, offering the Hugo robotic-assisted surgery system. Medtronic offers the Hugo robotic-assisted surgery system through its acquisition of Mazor Robotics in 2018.



Key features of Hugo include its modular design for efficient setup, its slimmer profile compared to other systems, and its ability to be utilized in hybrid operating rooms. While later to market than pioneering systems like ISGR&rsquo;s, Hugo aims to bring robotic precision to commonly performed procedures like spine surgeries first.



Medtronic has raised its <a href="https://www.bizjournals.com/twincities/news/2023/08/22/medtronic-q1-fiscal-2024-outlook.html">financial outlook</a> for the upcoming year following better-than-expected sales and earnings in the first quarter of fiscal 2024. The company now expects its full-year earnings to be between $5.08 and $5.16 per share, an increase from the previously projected range of $5 to $5.10 per share.



Therefore, now could be a good time for investors to scoop up shares of MDT, with each of its four segments delivering 6% organic revenue growth so far in 2024.



On the date of publication, Matthew Farley did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed are those of the writer, subject to the<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/"> InvestorPlace.com Publishing Guidelines</a>.
<div>Matthew started writing coverage of the financial markets during the crypto boom of 2017 and was also a team member of several fintech startups. He then started writing about Australian and U.S. equities for various publications. His work has appeared in MarketBeat, FXStreet, Cryptoslate, Seeking Alpha, and the New Scientist magazine, among others.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT793992">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/02/wall-street-legend-issues-urgent-ai-code-red/?cid=MKT781156&amp;eid=MKT793990">&ldquo;America&rsquo;s Top Trader&rdquo; Issues A.I. Code Red: Act Now or Miss Out</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793999">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/03/7-robotic-surgery-stocks-to-buy-for-the-future-of-healthcare/">7 Robotic Surgery Stocks to Buy for the Future of Healthcare</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

7 Robotic Surgery Stocks to Buy for the Future of Healthcare

Smith and Nephew plc (SNN) is down -1.18%% today. SNN has an Overall Score of 52. Find out what this means to you and get the rest of the rankings on SNN!See Full SNN ReportSNN stock closed at $27.01 and is down -$0.32 during pre-market trading. Pre-market tends to be more volatile due to significantly lower volume as most

Smith & Nephew plc (SNN) is lower by 1.18% Monday In Premarket Trading

Smith & Nephew goes ex dividend Monday

Overall market sentiment has been high on Smith and Nephew plc (SNN)  stock lately. SNN receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator. Smith and Nephew plc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on SNN!See Full SNN ReportWhat is Stock

Where Will Smith & Nephew plc (SNN) Stock Go Next After It Is Down 1.53% in a Week?

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Smith & Nephew Snats (SNN – Research Report), Ocuphire Pharma (OC...

Analysts Offer Insights on Healthcare Companies: Smith & Nephew Snats (SNN), Ocuphire Pharma (OCUP) and Vertex Pharmaceuticals (VRTX)